Clinical Trials Logo

Pain, Postoperative clinical trials

View clinical trials related to Pain, Postoperative.

Filter by:

NCT ID: NCT06088420 Recruiting - Post Operative Pain Clinical Trials

Analgesic Efficacy of Different Nerve Blocks in Postoperative Cesarean Section

Start date: October 2023
Phase: N/A
Study type: Interventional

comparing analgesic efficacy of different nerve blocks on post operative cesarean sections.

NCT ID: NCT06086535 Recruiting - Post Operative Pain Clinical Trials

Intercostal Nerve Cryoanalgesia vs BRILMA Block for Minithoracotomy on Cardiac Surgery

Start date: February 18, 2023
Phase:
Study type: Observational

Patients undergoing cardiac surgery by minithoracomy present severe acute postoperative pain. Cryoanalgesia of the intercostal nerves and BRILMA block can provide a solution for this postoperative pain. The main aim of this study is to compare the postoperative analgesia provided by BRILMA block and intercostal nerve cryoanalgesia in patients undergoing cardiac surgery by minitoractomia.

NCT ID: NCT06079047 Recruiting - Post Operative Pain Clinical Trials

Perineural Dexamethasone in the Adductor Canal Block

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

Postoperative pain management in total knee arthroplasty (TKA) surgery is a real challenge for the anesthesiologist. Effective pain control must be provided while preserving the mobility to ensure early rehabilitation. The adductor canal block is an effective way to induce sensory block without motor block. However, the major disadvantage of this block is the duration of sensory block which may be insufficient for postoperative pain management in TKA surgery. Many studies have focused on finding molecules that can prolong sensory block without the need for a perineural catheter and dexamethasone is among the most studied molecules(1, 2). Hence, our study aims to evaluate the added value of perineural dexamethasone in the adductor canal block in TKA surgery. [

NCT ID: NCT06077422 Recruiting - Pain, Postoperative Clinical Trials

Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

Start date: January 11, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this pilot study is to describe and compare Ultrasound-Guided Erector Spinae Plane (ESP) Blocks using Exparel® (bupivacaine liposome injectable suspension) to Marcaine® (bupivacaine hydrochloride) for pain management and outcomes after cardiac surgeries.

NCT ID: NCT06077214 Recruiting - Clinical trials for Bariatric Surgery Candidate

Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients

Start date: January 31, 2023
Phase: Phase 1
Study type: Interventional

Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is up to 6 hours. The liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. Typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. Therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.

NCT ID: NCT06071988 Recruiting - Pain Clinical Trials

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Start date: November 2, 2023
Phase: Phase 3
Study type: Interventional

Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to traumatic or post-operative peripheral neuropathy. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to traumatic or post-operative peripheral neuropathy.

NCT ID: NCT06071936 Recruiting - Pain Clinical Trials

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Start date: November 2, 2023
Phase: Phase 3
Study type: Interventional

Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to traumatic or post-operative peripheral neuropathy. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to traumatic or post-operative peripheral neuropathy.

NCT ID: NCT06066684 Recruiting - Clinical trials for Osteo Arthritis Knee

Pain Phenotyping in Knee OA: a Pilot Trial

Start date: September 18, 2023
Phase:
Study type: Observational

Osteoarthritis (OA) is disease in which the joint breaks down, causing pain. The decision to surgically replace the knee, a procedure called total knee arthroplasty (TKA), depends on x-ray results as well as pain and dysfunction. Despite TKA resulting in good outcomes for most patients, between 1 in 10 and 1 in 5 patients remain in significant pain - i.e., are 'TKA non-responders'. Two pain conditions - myofascial pain syndrome (MPS) and central sensitization - frequently coexist with signs of OA and may contribute to a TKA non-responder profile. MPS, caused by knots within skeletal muscle, can contribute to an OA patient's pain and dysfunction. In central sensitization, faulty pain sensing leads to increased pain sensitivity. However, there is currently no established process to identify these sources of pain and potential associated TKA non-responder risk. Our research aims conduct a pilot study to examine the impact of pain diagnosis tools to help orthopedic surgeons identify potential TKA nonresponders. This new approach may increase healthcare efficiency (reduce TKA waitlist and length of hospital stay), and help patients receive the right care at the right time.

NCT ID: NCT06061068 Recruiting - Quality of Life Clinical Trials

Hernia Belt in Laparoscopic Inguinal Hernia Repair

Start date: July 17, 2023
Phase: N/A
Study type: Interventional

In this study, the investigators aimed to investigate the effect of hernia belt on postoperative complications and quality of life for patients who underwent laparoscopic inguinal hernia repair. Outcomes include hernia recurrence (patient-reported and clinical exam), postoperative complications within 3 months (seroma and hematoma development, wound infection, abdominal bloating and foreign body sensation), pain (visual analog scale,VAS), health-related quality of life (36-item short-form health survey, SF-36). Follow up by physical examination, ultrasonography and telephone.

NCT ID: NCT06056245 Recruiting - Clinical trials for Chronic Kidney Diseases

Methadone Pharmacokinetics in End-stage Renal Disease

MCKD
Start date: April 5, 2024
Phase:
Study type: Observational

The goal of this observational study is to describe the influence of renal function on the pharmacokinetics of methadone used through an intravenous patient-controlled analgesia (IV-PCA) pump for the management of acute postoperative pain. After surgery the participants will use an IV-PCA of methadone and blood samples will be withdrawn to measure the plasmatic levels of it. The main question the study aims to answer is: • Is the pharmacokinetic of methadone used in an IV-PCA pump impaired in patients with chronic kidney disease?